What is known and objective: Pregabalin is used for neuropathic and postherpetic pain and generalized anxiety. The aim of this study was to obtain the onset profiles of adverse events (AE) related to falls (AEFs) such as "somnolence," "dizziness," "loss of consciousness" and "fall" onset and several clinical factor combinations such as age and administered dose, using spontaneous reporting system (SRS) analysis such as the US Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database.
| WHAT IS K NOWN AND OBJEC TIVE S
Pregabalin is a novel anticonvulsant used in the adjunctive therapy for partial epilepsy. [1] [2] [3] It is also used to treat neuropathic pain, postherpetic pain and generalized anxiety. Pregabalin binds selectively to the α 2 δ subunit of voltage-gated calcium channels and reduces presynaptic neurotransmitter release. 4, 5 It causes several adverse events (AEs) such as dizziness, somnolence, dry mouth, oedema, blurred vision, weight gain and abnormal thinking. 6 Somnolence and dizziness are the common AEs related to pregabalin treatment, which increase in a dose-dependent manner and represent the frequent reasons for discontinuation of treatment. [7] [8] [9] As pregabalin treatment is associated with dizziness and somnolence, it could increase the occurrence of accidental injury (fall) in the older population. 10 The AEs related to falls (AEFs) of pregabalin are well recognized by clinicians. In controlled trials of pregabalin, dizziness was experienced by 31% of pregabalin-treated patients compared to 9% of placebo-treated patients; somnolence was experienced by 22% of pregabalin-treated patients compared to 7% of placebo-treated patients. 6 Based on the previous studies of pregabalin therapy, somnolence and dizziness are transient and the most pronounced during the first week, in a dose-dependent manner, with a lower incidence thereafter. 7, 9, [11] [12] [13] However, detailed time-to-onset profiles of pregabalin-induced AEFs are not clear.
Spontaneous reporting system (SRS) has been recognized as a primary tool for pharmacovigilance that reflects the realities of clinical practice. [14] [15] [16] Clinicians enter their concerns about potential drug-induced AEs during their normal diagnostic assessments of patients into the SRS. The US FDA Adverse Event Reporting System (FAERS) is the largest and best-known SRS database in the world.
The regulatory authority in Japan, the Pharmaceuticals and Medical Devices Agency (PMDA), has released the SRS for the Japanese Adverse Drug Event Report (JADER) database. In the JADER database, brief AE profiles, except for the detailed AEFs, associated with pregabalin in patients with or without cancer are recorded.
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The aim of this study was to obtain novel information on the onset profiles of AEFs and several clinical factor combinations such as age and administered dose, using the FAERS and JADER database.
| ME THODS

| Data sources
We used two SRS data sources: (a) the FAERS database (www.fda. gov) and (b) the JADER database (www.pmda.go.jp). All data from the FAERS and JADER databases were fully anonymized by the regulatory authorities before we used them. We have integrated the relational database for each SRS database using filemaker pro 12
software (FileMaker Inc, Santa Clara, CA, USA).
The FAERS database consists of seven categories: patient demographic information (DEMO), drug information (DRUG), AEs (REAC), outcome (OUTC), report sources (RPSR), start and end dates of administration (THER) and prescription intention (INDI). In the DRUG category, the causality of each drug was assigned a code based on its association with AEs such as "primary suspected drug (PS)," "secondary suspected drug," "concomitant drug" or "interacting drug." In this study, we only used PS for analyses. We followed the FDA's recommendation to adopt the most recent case numbers to identify duplicate reports from the same patient and exclude them from the analyses.
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The JADER database consists of four categories: patient demographic information (DEMO), drug information (DRUG), AEs (REAC) and primary disease (HIST). The JADER database does not contain key codes for identifying the patient; therefore, duplicate cases could not be excluded. In the DRUG category, the causality of each drug was assigned a code based on its association with AEs such as "suspected drug," "concomitant drug" or "interacting drug." In this study, we only used the "suspected drug" code for analyses in the JADER database.
| Definition of adverse events
Preferred terms (PTs) from the Medical Dictionary for Regulatory
Activities were used to define medical terminologies in the SRS da- 
| Analysis
For analysis of the SRS reports, data mining algorithms were utilized to identify the drug-associated AEs by disproportionality analysis.
The reporting odds ratio (ROR) was developed for use with SRS data as a relative risk measure for drug-associated AEs. 19 We used ROR to analyse the association between pregabalin and AEFs. ROR represented the odds of a specific AE caused by the drug of interest compared to the odds of a specific AE caused by all other drugs and is calculated based on the two-by-two contingency table (Figure 1 ).
ROR is expressed as point estimates with 95% confidence interval (CI). The signal is considered positive when the lower limit of 95% CI is >1, and the number of reports is ≥2. 14 The reports were stratified by age as follows: <60 years age group and ≥60 years age group.
The use of ROR allows for an adjustment through multiple-logistic regression analysis and offers the advantage of controlling for covariates. 20, 21 We calculated the adjusted ROR based on previous reports. 20, 21 For the adjusted ROR calculations, only reports with complete information for the reporting year and age were extracted.
F I G U R E 1 Two-by-two contingency table for analysis
Adverse event All other adverse event
To construct the multiple-logistic model, reporting year and stratified age groups were coded. The following logistic model was used for analysis:
where Y = reporting year and A = age. The records with the completed reporting year and age were used for the multiple-logistic regression analysis. The adjusted RORs were calculated using the <60 years age group as the reference group. The likelihood ratio test can be used to evaluate the effect of adding a particular term. As a difference of −2 log-likelihood follows the chi-square distribution with one degree of freedom, adding the interaction term, in this case, was statistically significant (P < 0.05).
In the JADER database, the median of the data and quartiles were utilized for the evaluation of the time-to-onset data. Time-to-onset duration was calculated from the administration of the subject's first prescription to the occurrence of the AEs. We excluded reports that did not have complete AE occurrence and prescription start times. It was necessary to consider right truncation when evaluating the time to onset of AEs. We determined an analysis period of 3 weeks after the start of administration to focus on the onset of AEs after the patients' first prescription. Data analyses were performed using the jmp 11.0 (SAS Institute Inc, Cary, NC, USA). The reports were stratified by dose as follows: ≤75 and ≥100 mg/d.
| Ethical approval
Ethical approval was not sought for this study because the study was an observational study without any research subjects. 
| RE SULTS
dizziness, loss of consciousness and fall were 7.58 (7.15-8.03), 3.25 (3.09-3.41), 1.67 (1.48-1.88) and 1.80 (1.69-1.76), respectively.
| D ISCUSS I ON
In this study, we evaluated the relationship between pregabalin and AEFs using data from the SRS database. The crude RORs of AEFs such as somnolence and dizziness were higher than 1 in both the SRS databases. Our results suggest that pregabalin increases AEFs and support previous observations on AEFs related to pregabalin. The results obtained after adjusting the RORs suggested that age may influence AEFs. We also applied time-to-onset analysis to validate the results, which provided novel insights into the time-to-onset of AEFs-that is, over 50% of AEFs were observed within 2 days in the real-world data set.
The adjusted RORs for the tested AEFs were significantly higher in the ≥60 years age group than in the <60 years age group, for both the databases. Renal elimination and linear pharmacokinetics of pregabalin require dose adjustment in the renally impaired or elderly patients. 6, 22 Despite dose adjustment, the ≥60 years age group had an increased risk of AEFs compared to that in the <60 years age group.
Previous studies have reported that somnolence and dizziness are the most pronounced during the first week of treatment, with a sharp fall in incidences from week 2. a daily basis. Over 50% of AEFs (four PTs) were observed within 2 days of administration, and the median for AEFs onset was 2 days.
Our results revealed that most AEFs were observed on the day of administration when the pregabalin dose was ≤75 mg, and the day after dose administration when the pregabalin dose was ≥100 mg.
Pregabalin requires adequate upward dose titration, gradually initiated and titrated based on response and tolerability. 23 Therefore, in patients with pregabalin dose ≥100 mg, the peak might be observed on the day after administration. Generally, dizziness and somnolence began shortly after the initiation of pregabalin therapy and occurred more frequently at the higher doses. 6 The starting dose may be reduced in drug-sensitive or elderly patients and could be 25 mg, twice daily.
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Falls are common health events and a serious problem among older adults. Several medication classes, including benzodiazepines, antidepressants, sedative hypnotics, antipsychotics, and some cardiac drugs and diuretics, have been associated with an increased risk of falls due to dizziness, sedation, impaired motor coordination and postural disturbances. [25] [26] [27] Cancer patients with pain who receive pregabalin treatment are often treated with opioids, which have inhibitory effects on the central nervous system. It is reported that the ≥65 years age group and co-administration of strong opioids are risk factors for somnolence or dizziness in patients treated with pregabalin for neuropathic pain. 13 Co-administration leads to drug interactions and may be an important risk factor for falls. [28] [29] [30] A majority of patients, 54.2% in the FAERS and 67.9% in the JADER, experienced polypharmacy (data not shown). However, since the profiles of co-administered drug were complicated, it is difficult to evaluate the risk of co-administered drug that might affect AEFs in this study.
More careful dose titration is recommended for elderly patients and those receiving concomitant drugs.
Pregabalin may cause AEFs and influence the ability to drive or use machines. 6 Medical professionals should advise patients not to drive, operate complex machinery or engage in other potentially hazardous activities until pregabalin's ability to affect the performance of these activities is known. further.
In this study, we applied time-to-onset analysis. After extraction of the combinations with complete information on the date of starting medication and the date of AE onset, time-to-onset duration was calculated from the beginning of a subject's first prescription to the occurrence of the AEs. In the FAERS database, matching between the date of AE onset and the date of starting treatment of each individual drug is difficult because of the database structure. Therefore, we used the JADER database for the time-to-onset analysis in this study.
Spontaneous reporting system is a passive reporting system and does not always contain details, such as titration schedule, to appropriately evaluate an event. Since the number of missing cases of AE occurrence and prescription start times was considerable in the time-to-onset analysis, further prospective studies with a larger sample size are required. SRS is influenced by many factors such as the length of time on the market, publicity about an AE, over-reporting, under-reporting and other confounders. There is a lack of comparison group and missing data on patient characteristics. Owing to these limitations, the crude RORs without logistic regression analysis do not indicate the risk of AE occurrence in absolute terms. 14, 20, 21 By using logistic regression analysis, we partially refined the results with a dedicated correction to detect possible confounders present in the database. It may be acceptable to compare the adjusted RORs of a particular AE within a particular context. Additionally, we obtained time-to-onset profiles for the AEFs. Thus, these data may enhance the information available to clinicians and improve the management of pregabalin-induced AEFs.
| WHAT IS NE W AND CON CLUS I ON
This study was the first to evaluate the relationship between pregabalin and AEFs using the SRS analysis strategy. AEFs such as somnolence, dizziness, loss of consciousness and fall were observed in the pregabalin-treated patients. The risk of AEFs in the ≥60 years age group might increase compared to that in the <60 years age group.
Most AEFs occurred within the first week after administration, and the median for AEF onset was 2 days. Our results show that patients should be closely monitored for AEFs during the first week after pregabalin administration.
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